Publications by authors named "Yanyun Dou"
Background: Antiretroviral therapy (ART) has transformed HIV management, with various regimens available. Dolutegravir (DTG) plus lamivudine (3TC) dual therapy is now the one of the first line regimens.
Methods: A retrospective, observational study included treatment naïve people living with HIV (PLWH) with baseline HIV RNA viral load (VL) greater than 500,000 copies/mL from March 2020 to June 2022.
Objectives: Dolutegravir + lamivudine (DTG + 3TC) is a first-line regimen for people with HIV. However, there are still concerns about its efficacy in people with tuberculosis (TB)/HIV due to the lack of available evidence and drug-drug interaction with rifampicin.
Methods: A single-centre retrospective observational case series was conducted in Guangxi Zhuang Autonomous Region, China.
Article Synopsis
- Direct-acting antiviral agents (DAAs) have significantly improved the treatment of Hepatitis C (HCV), but an effective and safe treatment for patients co-infected with HIV remains a challenge, especially in low-resource settings.
- This study evaluated the safety and efficacy of a 12-week treatment with sofosbuvir and velpatasvir in chronic HCV/HIV-1 co-infected patients who were already on an antiretroviral regimen.
- Among 243 patients in the study, 97% achieved a sustained virologic response (SVR12) after treatment, demonstrating the high effectiveness of this regimen across different HCV genotypes.
Background: There is a high prevalence of anemia among people living with HIV in Guangxi, China. Therefore, we investigated anemia and opportunistic infections in hospitalized people living with HIV and explored the risk factors related to anemia in people living with HIV to actively prevent anemia in people living with HIV.
Methods: We retrospectively studied people living with HIV admitted to Guangxi Chest Hospital from June 2016 to October 2021.